ArticleJournal of biomedical materials research. Part A2026
Safety, Distribution, and Pharmacokinetics of Biodegradable P(AAm-co-MAA) Nanogels Following Systemic Administration in Mice.
Article in Journal of biomedical materials research. Part A, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Systematic analysis of the fate of hydrogel nanoparticles after in vivo administration is essential for their clinical translation. Biodegradable, disulfide-crosslinked synthetic nanogels are a promising platform for the delivery of therapeutic molecules, but their biodistribution and clearance profiles remain underexplored compared to other solid nanoparticles. In this study, we investigated the safety, pharmacokinetics, tissue, and cellular distribution profiles of poly(acrylamide-co-methacrylic acid) (P(AAm-co-MAA)) nanogels following a single intravenous or intraperitoneal injection. The nanogels exhibited rapid clearance from plasma, followed by early distribution primarily to the kidneys, liver, and small intestine. Within the liver, the nanogels showed preferential uptake by endothelial cells and resident macrophages. We further revealed organ-specific differences in nanogel retention and clearance, with highly perfused organs demonstrating parallel clearance behavior with plasma, while organs such as the kidneys and small intestine served as sites of longer nanogel retention. Single injections of P(AAm-co-MAA) nanogel suspension did not induce any systemic innate immune activation nor organ-specific toxicity, demonstrating a promising safety profile. These findings provide new insights into the in vivo behavior of redox-responsive nanogels and provide a framework for their rational design and clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.